BPC-157 + Epitalon Stack: When to Pick One Over the Other (or Both)

What the two peptides are

BPC-157 is a synthetic peptide of 15 amino acids, Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, with a molecular weight of about 1,419.5 g/mol, described as a fragment of a protein first isolated from human gastric juice. It is made as a free base or as an acetate salt, and FDA treats those as two different bulk substances [1].

Epitalon (also spelled epithalon) is a synthetic tetrapeptide, Ala-Glu-Asp-Gly, about 390 g/mol as the free base and about 450 g/mol as the acetate. It was designed from the amino-acid content of epithalamin, a polypeptide extract of animal pineal gland. FDA treats epitalon and epithalamin as different substances, so the older epithalamin studies are not studies of epitalon [2].

Neither is approved. FDA's July 2026 review found no approved product containing BPC-157 in any country it searched and no US Pharmacopeia or National Formulary monograph for it [1]. For epitalon it found no monograph, no approved product in the countries it checked, including Canada, Australia and the UK, and none authorized by the European Medicines Agency [2]. Epitalon did hold an FDA orphan drug designation for retinitis pigmentosa, granted September 2, 2010 and withdrawn January 6, 2016 [2]. A 2015 analysis found epitalon in two illegal pharmaceutical preparations sold for cancer, old age and retinitis pigmentosa [8].

What human data exist for BPC-157

FDA's review turned up five small human studies of BPC-157: meeting abstracts, a retrospective chart review, a single-arm pilot and a 2-person pilot [1]. A 2026 systematic review searched to June 1, 2026 and found three studies covering 30 patients, all of poor methodological quality, with certainty of evidence rated very low. The reviewers concluded BPC-157 should not be used clinically outside ethically approved, regulated, high-quality trials [3].

Those three studies:

• Knee pain. A retrospective chart review at one Florida clinic covered 17 patients, 16 of whom were reached by phone. Twelve received BPC-157 alone and four received it with thymosin beta-4. Eleven of the 12 BPC-157-only patients (91.6%) reported significant improvement. There was no control group, no validated outcome tool, and patients recalled their results [9].
• Interstitial cystitis. Twelve women aged 39 to 76 who had not responded to pentosan polysulfate received 10 mg of BPC-157 injected around the bladder wall in one procedure. Ten reported complete symptom resolution and two about 80% improvement. Single arm, no placebo, patient-rated [10].
• Intravenous safety. Two adults received 10 mg on day 1 and 20 mg on day 2, with no measurable change in the heart, liver, kidney, thyroid or glucose markers tested and no side effects reported. Two people cannot establish safety [11].

A fourth report is a phase 2 trial in which 53 people with mild to moderate ulcerative colitis were randomized to an 80 mg BPC-157 enema or placebo daily for two weeks. Its only report is a 2005 conference summary, which says the enema was well tolerated with no difference in adverse events from placebo. FDA said it has too little detail to judge effectiveness, and no full paper exists [1].

FDA found no human study of BPC-157 given by mouth, by subcutaneous injection, by nasal spray or on the skin [1], so safety and effectiveness by those routes have not been studied in people.

Safety

In the small human studies FDA reviewed, no serious adverse events were reported, but the studies were short and small and gave limited safety information [1]. FDA's search of its adverse-event database through December 4, 2025 found three reports, all for injectable BPC-157: injection-site redness and swelling lasting nine days in a patient who also used a compounded thymosin; shortness of breath leading to an emergency room visit, with no other detail; and widespread skin and gum darkening that recurred when the person was re-exposed to a BPC-157 plus TB-500 research product. FDA said it cannot tell whether BPC-157 caused any of them [1].

FDA concluded there is insufficient clinical safety information to characterize BPC-157's safety profile [1]. In 28-day intramuscular animal studies, BPC-157 shortened clotting time (aPTT) in rats and prolonged it in dogs, and raised liver enzyme (ALT), glucose and triglyceride levels; longer studies and cancer-risk studies were not available [1]. How the peptide works in people is unknown: FDA says its molecular targets have not been identified and its mechanisms remain poorly understood [1].

What human data exist for epitalon

FDA found three human studies of epitalon: two sublingual studies in night-shift workers and one eye injection in retinitis pigmentosa. None was in people with insomnia, and no clinical study assessed epitalon's safety [2].

• Sublingual, night-shift workers (Ivko 2021, as described by FDA). Seventy-five healthy women aged 40 to 50 were enrolled, mostly night-shift workers; 40 had low melatonin output and were split into two groups of 20. A spray delivering about 0.5 mg per day, or placebo, was given for 20 days. Urinary 6-sulfatoxymelatonin rose about 1.7-fold on epitalon and did not change on placebo. Mood and physical condition were described as improved in 83% versus 25%, but no sleep outcomes were measured and blinding was not specified [2].
• Retinitis pigmentosa (Khavinson 2002). Epitalon was injected beside the eye. The abstract reports a 'positive clinical effect in 90% of the cases' but gives no sample sizes or design details. It has not been replicated and is not a modern randomized trial [12].

The telomere claim rests on cell culture. Adding epitalon to telomerase-negative human fetal fibroblast cultures induced the catalytic subunit of telomerase, telomerase activity and telomere elongation [13]. A 2025 laboratory study found dose-dependent telomere lengthening in normal cells through telomerase upregulation, and also found significant telomere extension in breast cancer cell lines through alternative lengthening of telomeres [14].

FDA warned that because epitalon activates telomerase and lengthens telomeres, and longer telomeres are generally linked to higher cancer risk, it has a mechanistic potential to be carcinogenic. The mouse studies of cancer and chromosome damage were too limited (one fixed dose, female mice only, short exposure) to show safety [2]. A 2026 narrative review concluded epitalon is 'biologically active but clinically unproven', with no adequately powered randomized trial and inadequate pharmacokinetic, dose-ranging and long-term safety data [15]. FDA found no pharmacokinetic data for epitalon at all [2].

FDA's adverse-event database search through December 8, 2025 and its food and supplement complaint search through December 5, 2025 retrieved no epitalon reports [2].

The combination: what is known

None of the human studies of either peptide gave BPC-157 and epitalon together, so their combined safety and effectiveness are unknown.

The idea that the two act on complementary pathways cannot be checked: FDA says BPC-157's molecular targets have not been identified [1], and how epitalon changes melatonin in the body is unknown [2]. FDA found no human pharmacokinetic data for BPC-157 given orally, subcutaneously, nasally or on the skin, and none for epitalon [1][2].

HHS's draft enforcement-discretion policy names both peptides. Its conditions include a single active ingredient, a patient-specific prescription, a bulk substance from an FDA-registered manufacturer with a valid certificate of analysis, and a label reading 'This is a compounded drug product. Not for resale.' [4][5].

Where each peptide stands legally

Both were in FDA's category for bulk substances that may present significant safety risks and now sit in the 'nominated but withdrawn' table, after the groups that nominated them withdrew. Removal came from that withdrawal, not from a finding of safety [16]. Neither appears in any of the three categories on FDA's list for state-licensed pharmacies and physicians (updated May 14, 2026), so FDA's category 1 policy of generally not acting against compounders does not cover either one [17][18].

FDA staff reviewed both in July 2026 and recommended against adding either to the list of bulk substances that can be used in compounding. For BPC-157 the reasons were poor chemical characterization, little safety and immunogenicity information, insufficient evidence for ulcerative colitis, and the existence of approved treatments for it [1]. For epitalon, FDA evaluated only insomnia, found no study of epitalon in people with insomnia and no clinical safety data, and cited the immunogenicity risk of subcutaneous injection plus the many approved insomnia drugs [2]. On July 23 and 24, 2026 the Pharmacy Compounding Advisory Committee voted in favor of adding both, against the staff recommendation; news reports give the BPC-157 vote as 8 to 6 with 1 abstention. Those votes are advice only [19][4].

On October 28, 2026 HHS filed a draft enforcement-discretion policy naming six peptides including both of these, scheduled for Federal Register publication on October 30, 2026 with public comment open for two weeks after publication. HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding with a listed peptide while FDA's list is developed through rulemaking, if the policy's conditions are met [5][4]. The terms differ: for BPC-157, the acetate form by subcutaneous, intramuscular, oral or topical use, with nasal, rectal and intravenous not listed; for epitalon, the acetate form by subcutaneous or intramuscular injection in intermittent courses [4][5].

None of this is an approval. The notice says the policy 'does not establish any rights for any person and is not binding on HHS or the public', and HHS may revisit it. Compounded drugs are not FDA-approved: FDA does not review their safety, effectiveness or quality before marketing [5].

Sport

WADA's Prohibited List names BPC-157 in class S0 (non-approved substances), which covers substances with no current approval by any governmental regulatory health authority for human therapeutic use. It is prohibited at all times, in and out of competition, and the 2026 List has been in force since January 1, 2026 [6]. BPC-157 was first named as an example under S0 in the 2022 List and remains named in the 2027 List [20][7].

Epitalon is not named in the 2026 List or the 2027 List. The S0 class names BPC-157 only as an example ('including but not limited to'), and the List does not state whether epitalon falls within S0 [6][7].

So which one, or both?

The available evidence does not establish that either peptide is safer or more effective than the other, or that combining them is safe [1][2][3].

BPC-157 has more human reports, but they are a chart review, two small single-arm pilots and meeting abstracts, and a 2026 systematic review rated the certainty very low and advised against clinical use outside trials [9][10][11][3]. FDA also flagged animal signals: clotting time changes and raised liver enzymes, glucose and triglycerides [1]. Epitalon's human data are three small studies, none assessing safety, and FDA raised a theoretical cancer concern tied to telomerase activation [2][15].

For tissue repair in the knee or bladder, only BPC-157 has even small human reports, all uncontrolled. For a melatonin effect, only epitalon has a controlled human biomarker study, and it measured a urinary melatonin metabolite in 40 women over 20 days, not sleep [2].